UCap Oceanwide Fund was among the participants as the database management software developer pulled in $18.6m in early-stage financing.

HY Energy and Yake Food-backed starch sugar additive manufacturer Zhejiang Huakang Pharmaceutical is set to go public in Shanghai.

Gree and Shanghai Kindly-backed, respiratory-focused medical device and drug developer Resproly has closed a round led by CAS Investment Management.

CAS Investment Management, a subsidiary of Chinese Academy of Sciences, has backed medical devices developer Resproly’s series B round.

Bertelsmann Asia Investments contributed to a series A round that will fund preclinical development of NeoX's immuno-oncology drug pipeline.

Chishima Real Estate, M3, Miraca, Nippon Life, POC Clinical Research, Reprocell, Toho Holdings and Zenoaq have all scored exits after the cell therapy provider went public.

Digital Garage and Bank of Yokohama’s $28.8m investment vehicle will back companies focusing on financial technology and regional revitalisation.

Clal Insurance, Ayalon Insurance, MS&AD, FWD, Reale Mutua and LB Group were among the limited partners for the venture capital firm's sophomore fund.

The venture capital firm is teaming up with Illumina on a genomics incubator and with China Pacific Insurance on a medical technology fund.

ADM, Rich’s Products, Müller Group and Tyson Foods have all backed a $26.8m convertible note round for the cellular meat developer that included new and returning investors.